Standard BioTools Reports Q2 2026 Financial Results with Revenue Decline and Net Loss

Standard BioTools Inc. reported its financial results for the second quarter of 2026, revealing a total revenue of $20.1 million, a decrease of 8% from $21.8 million in the same period last year. For the first half of 2026, revenue totaled $41.3 million, down 2% from $42.0 million in the first half of 2025. The decline in revenue was primarily attributed to a 10% drop in consumables revenue and an 8% decrease in services and other revenue, although instrument revenue remained relatively stable. The company recorded a gross profit of $10.5 million for the quarter, resulting in a gross margin of 52.4%, compared to 48.8% in the prior year.

In terms of expenses, Standard BioTools reported total operating expenses of $35.9 million for the second quarter, slightly down from $36.3 million a year earlier. Notably, research and development expenses plummeted by 68% to $2.0 million, reflecting the impact of restructuring efforts initiated in 2025. Selling, general, and administrative expenses also decreased by 42% to $16.4 million, driven by reduced personnel costs. The company incurred a net loss from continuing operations of $21.5 million for the quarter, compared to a loss of $17.7 million in the same period last year.

A significant operational development for Standard BioTools was the completion of the sale of its SomaScan Business to Illumina on January 30, 2026, which generated net cash consideration of $388.2 million. This transaction resulted in a pre-tax gain of $172.3 million, contributing to a net income from discontinued operations of $136.5 million for the first half of 2026. The company is also in the process of merging with Treeline Biosciences, with the merger expected to close in the second half of 2026, subject to customary closing conditions.

As of June 30, 2026, Standard BioTools reported total assets of $627.2 million, up from $567.8 million at the end of 2025, largely due to increased cash and cash equivalents, which rose to $270.0 million from $120.9 million. The company’s total liabilities decreased significantly to $87.2 million from $143.5 million, primarily due to the classification of certain liabilities related to discontinued operations. The company’s stockholders’ equity increased to $540.0 million, reflecting the gain from the sale of the SomaScan Business.

Looking ahead, Standard BioTools anticipates that its ongoing restructuring efforts and the merger with Treeline will position the company for future growth. The company expects to leverage its enhanced financial position and operational efficiencies to drive innovation and expand its market presence in the life sciences tools industry. However, the company also noted that interim results may not be indicative of future performance, emphasizing the need for continued focus on operational improvements and strategic initiatives.